KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Novavax (NVAX) Enterprise Value (2016 - 2025)

Novavax has reported Enterprise Value over the past 16 years, most recently at -$735.1 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$735.1 million for Q4 2025, up 20.37% from a year ago — trailing twelve months through Dec 2025 was -$735.1 million (up 20.37% YoY), and the annual figure for FY2025 was -$735.1 million, up 20.37%.
  • Enterprise Value for Q4 2025 was -$735.1 million at Novavax, up from -$762.9 million in the prior quarter.
  • Over the last five years, Enterprise Value for NVAX hit a ceiling of -$10.3 million in Q2 2022 and a floor of -$2.1 billion in Q2 2021.
  • Median Enterprise Value over the past 5 years was -$590.4 million (2023), compared with a mean of -$733.3 million.
  • Biggest five-year swings in Enterprise Value: skyrocketed 99.5% in 2022 and later crashed 5417.86% in 2023.
  • Novavax's Enterprise Value stood at -$1.5 billion in 2021, then surged by 99.32% to -$10.3 million in 2022, then crashed by 5417.86% to -$568.5 million in 2023, then plummeted by 62.38% to -$923.1 million in 2024, then rose by 20.37% to -$735.1 million in 2025.
  • The last three reported values for Enterprise Value were -$735.1 million (Q4 2025), -$762.9 million (Q3 2025), and -$612.3 million (Q2 2025) per Business Quant data.